Pain & Neuroscience, Drug Discovery & Disease Research Laboratory, Shionogi & Co., Ltd., Toyonaka, Osaka, Japan.
Eur J Pain. 2018 Feb;22(2):355-369. doi: 10.1002/ejp.1125. Epub 2017 Sep 26.
Approximately 40% of patients with chronic low back pain have a neuropathic component. In this study, we assessed the effects of analgesics on tactile hypersensitivity and walking distance in the rat cauda equina compression (CEC) model of neuropathic low back pain.
The effects of analgesics on tactile hypersensitivity were examined using the von Frey test in CEC and partial sciatic nerve ligation (pSNL) models. Effects on walking distance were assessed using a treadmill test. Levels of α2δ1 subunit and ATF-3 mRNA in dorsal-root ganglion (DRG) neurons and those of α2δ1 subunit protein in the spinal cord were determined using quantitative RT-PCR and western blotting, respectively. Histological features were assessed using immunohistological methods.
Histological changes indicating nerve damage (increase in ATF-3 mRNA, decrease in NF-200 and an increase in CD68 immunoreactivity) were observed in the CEC model. Duloxetine had analgesic effects in both models and improved walking distance in the CEC model. Pregabalin had analgesic effects in both models; however, the effect was weaker in the CEC model than in the pSNL model. α2δ1 subunit expression in DRG neurons and in the spinal cord was unchanged in the CEC model, but significantly increased in the pSNL model. Indomethacin had no analgesic effect in either model. Intrathecal yohimbine inhibited the effects of duloxetine with significant effects on depression.
These findings suggest that the analgesic effects of duloxetine are mainly mediated by the spinal monoamine system, independent of the antidepressant effects of this agent.
The findings of this study suggest that duloxetine may be an effective treatment of broad neuropathic pain states, including neuropathic low back pain. The analgesic effects of duloxetine might be mediated by alterations of the descending pain modulatory pathways in the spinal cord, independent of the antidepressant effects.
大约 40%的慢性腰痛患者存在神经病理性成分。在这项研究中,我们评估了镇痛药在大鼠马尾压迫(CEC)模型中神经病理性腰痛的触觉过敏和行走距离方面的作用。
使用 von Frey 试验在 CEC 和部分坐骨神经结扎(pSNL)模型中评估镇痛药对触觉过敏的作用。使用跑步机试验评估行走距离的影响。使用定量 RT-PCR 和 Western blot 分别测定背根神经节(DRG)神经元中α2δ1亚基和 ATF-3 mRNA 的水平以及脊髓中α2δ1亚基蛋白的水平。使用免疫组织化学方法评估组织学特征。
在 CEC 模型中观察到提示神经损伤的组织学变化(ATF-3 mRNA 增加、NF-200 减少和 CD68 免疫反应性增加)。度洛西汀在两种模型中均具有镇痛作用,并改善了 CEC 模型中的行走距离。普瑞巴林在两种模型中均具有镇痛作用;然而,在 CEC 模型中的作用弱于 pSNL 模型。DRG 神经元和脊髓中α2δ1亚基的表达在 CEC 模型中没有变化,但在 pSNL 模型中显著增加。吲哚美辛在两种模型中均无镇痛作用。鞘内育亨宾抑制了度洛西汀的作用,并对抑郁有显著影响。
这些发现表明,度洛西汀的镇痛作用主要通过脊髓单胺能系统介导,与该药物的抗抑郁作用无关。
这项研究的结果表明,度洛西汀可能是治疗广泛神经病理性疼痛状态(包括神经病理性腰痛)的有效药物。度洛西汀的镇痛作用可能是通过改变脊髓下行疼痛调节途径介导的,与抗抑郁作用无关。